XML 20 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 2,165 $ 2,177
Accounts receivables, net of allowance for credit losses of $90 million and $126 million as of December 31, 2021 and December 31, 2020, respectively 4,529 4,581
Inventories 3,818 4,403
Prepaid expenses 1,075 945
Other current assets 965 710
Assets held for sale 19 189
Total current assets 12,573 13,005
Deferred income taxes 596 695
Other non-current assets 515 538
Property, plant and equipment, net 5,982 6,296
Operating lease right-of-use assets 495 559
Identifiable intangible assets, net 7,466 8,923
Goodwill 20,040 20,624
Total assets 47,666 50,640
Current liabilities:    
Short-term debt 1,426 3,188
Sales reserves and allowances 4,241 4,824
Accounts payables 1,686 1,756
Employee-related obligations 563 685
Accrued expenses 2,208 1,780
Other current liabilities 903 933
Total current liabilities 11,027 13,164
Long-term liabilities:    
Deferred income taxes 784 964
Other taxes and long-term liabilities 2,578 2,240
Senior notes and loans 21,617 22,731
Operating lease liabilities 416 479
Total long-term liabilities 25,395 26,414
Commitments and contingencies, see note 12
Total liabilities 36,422 39,579
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; December 31, 2021 and December 31, 2020: authorized 2,495 million shares; issued 1,209 million shares and 1,202 million shares, respectively 57 57
Additional paid-in capital 27,561 27,443
Accumulated deficit (10,529) (10,946)
Accumulated other comprehensive loss (2,683) (2,399)
Treasury shares as of December 31, 2021 and December 31, 2020: 106 million ordinary shares (4,128) (4,128)
Stockholders' equity attributable to Teva shareholders 10,278 10,026
Non-controlling interests 966 1,035
Total equity 11,244 11,061
Total liabilities and equity $ 47,666 $ 50,640